How big is Sangamo Therapeutics, Inc.?

As of Jun 18, Sangamo Therapeutics, Inc. has a market capitalization of 118.55 million, with net sales of 63.76 million and a net profit of -80.75 million over the last four quarters. The company's shareholder's funds are 22.77 million, and total assets are 105.31 million.

Market Cap: As of Jun 18, Sangamo Therapeutics, Inc. has a market capitalization of 118.55 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Sangamo Therapeutics, Inc. reported net sales of 63.76 million and a net profit of -80.75 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 22.77 million, while total assets were reported at 105.31 million.

What does Sangamo Therapeutics, Inc. do?

Sangamo Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genomic therapies. As of March 2025, it reported net sales of $6 million and a net loss of $31 million, with a market cap of $118.55 million.

Overview: <BR>Sangamo Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genomic therapies that transform patients' lives within the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 6 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -31 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 118.55 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -5.13 <BR>Return on Equity: -1,621.75% <BR>Price to Book: 24.16<BR><BR>Contact Details: <BR>Address: 7000 MARINA BLVD, BRISBANE CA: 94005 <BR>Tel: ['1 510 9706000', '1 510 2368951'] <BR>Fax: 1 302 6555049 <BR>Website: https://www.sangamo.com/

Should I buy, sell or hold Sangamo Therapeutics, Inc.?

Who are in the management team of Sangamo Therapeutics, Inc.?

As of March 2022, the management team of Sangamo Therapeutics, Inc. includes Dr. Alexander Macrae as President and CEO, with Dr. Kenneth Hillan and several independent directors: Mr. Robert Carey, Dr. John Markels, Mr. James Meyers, and Ms. H. Stewart Parker.

As of March 2022, the management team of Sangamo Therapeutics, Inc. includes Dr. Alexander Macrae, who serves as the President, Chief Executive Officer, and Director. Additionally, the board features Dr. Kenneth Hillan as a Director, along with several independent directors: Mr. Robert Carey, Dr. John Markels, Mr. James Meyers, and Ms. H. Stewart Parker.

Is Sangamo Therapeutics, Inc. technically bullish or bearish?

As of August 25, 2025, Sangamo Therapeutics, Inc. has shifted to a mildly bearish trend, influenced by daily moving averages and mixed signals from MACD, while significantly underperforming the S&P 500 with a year-to-date return of -46.08%.

As of 25 August 2025, the technical trend for Sangamo Therapeutics, Inc. has changed from mildly bullish to mildly bearish. The current stance is mildly bearish, driven by daily moving averages indicating bearish momentum and a mixed signal from the MACD, which is mildly bullish on the weekly and monthly time frames. The Bollinger Bands show a bullish weekly trend but a mildly bearish monthly trend, while KST is mildly bullish weekly but mildly bearish monthly. The stock has underperformed significantly against the S&P 500, with a year-to-date return of -46.08% compared to the S&P 500's 12.22%.